Treprostinil Palmitil not checked
Insmed Incorporated · INS1009
FollowEvery change as it happens, and a Monday email
Trials
6 active
11 in total · 6 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Oral inhalation using a capsule-based dry powder inhaler device.”In the company’s words, NCT07481981 on ClinicalTrials.gov
- Tested for
- Interstitial Lung Disease (3 trials), Pulmonary Arterial Hypertension (2 trials), Pulmonary Hypertension (2 trials), Progressive Pulmonary Fibrosis, Hepatic Impairment
- Main trialPhase 3
- “The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.”In the company’s words, NCT07481981 on ClinicalTrials.gov
- Other names
- INS1009
Other drugs for Interstitial Lung Disease
- MosliciguatPulmovant, Inc. · Phase 3
- SC1011JOYO Pharma · Phase 2/3
- AnifrolumabAstraZeneca · Phase 3
- OlokizumabR-Pharm International, LLC · Phase 2/3
- NerandomilastBoehringer Ingelheim · Phase 3
- NAL ERTrevi Therapeutics · Phase 3
Coming up6
- 31 DecPhase 2/3 trial completes · ClinicalTrials.gov
- 7 Feb 2027Phase 1 trial completes · ClinicalTrials.gov
- 28 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 30 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- 31 Aug 2030Phase 3 trial completes · ClinicalTrials.gov
- 22 Jan 2031Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials11
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 28 Dec 2028 | A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH) | |
| Phase 3Recruiting | 30 Dec 2028 | Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | |
| Phase 3Recruiting | 31 Aug 2030 | A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF) | |
| Phase 3Recruiting | 22 Jan 2031 | An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | |
| Phase 2/3Active, not recruiting | 31 Dec 2026 | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) | |
| Phase 1Recruiting | 7 Feb 2027 | A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic Impairment | |
| Phase 2/3Completed | 1 Apr 2026 | An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) | |
| Phase 2Terminated | 26 Aug 2022 | A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH) | |
| Phase 2Completed | 14 Mar 2024 | A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease | |
| Phase 2Completed | 27 Mar 2025 | A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension | |
| Phase 1Completed | 12 Jan 2021 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026